Does the media prefer UTHR or REGN?

In the previous week, Regeneron Pharmaceuticals had 14 more articles in the media than United Therapeutics. MarketBeat recorded 45 mentions for Regeneron Pharmaceuticals and 31 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.43 beat Regeneron Pharmaceuticals' score of 0.85 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 23 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 22 Very Positive mention(s) 5 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media favor ARGX or UTHR?

In the previous week, United Therapeutics had 13 more articles in the media than argenex. MarketBeat recorded 31 mentions for United Therapeutics and 18 mentions for argenex. United Therapeutics' average media sentiment score of 1.43 beat argenex's score of 0.49 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 3 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral United Therapeutics 23 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MRNA or UTHR?

In the previous week, Moderna had 56 more articles in the media than United Therapeutics. MarketBeat recorded 87 mentions for Moderna and 31 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.43 beat Moderna's score of 0.64 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 38 Very Positive mention(s) 15 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 8 Very Negative mention(s) Positive United Therapeutics 23 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer UTHR or NTRA?

In the previous week, United Therapeutics had 3 more articles in the media than Natera. MarketBeat recorded 31 mentions for United Therapeutics and 28 mentions for Natera. United Therapeutics' average media sentiment score of 1.43 beat Natera's score of 1.15 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 23 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 24 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to UTHR or RVMD?

In the previous week, Revolution Medicines had 32 more articles in the media than United Therapeutics. MarketBeat recorded 63 mentions for Revolution Medicines and 31 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.43 beat Revolution Medicines' score of 0.78 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 23 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 27 Very Positive mention(s) 10 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Positive

United Therapeutics (UTHR) Competitors

$492.02 -20.68 (-4.03%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$487.38 -4.64 (-0.94%)

As of 06:37 AM Eastern

Compare

UTHR vs. REGN, ARGX, MRNA, NTRA, and RVMD

Should you buy United Therapeutics stock or one of its competitors? United Therapeutics's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), Natera (NTRA), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does United Therapeutics compare to Regeneron Pharmaceuticals?

United Therapeutics (NASDAQ:UTHR) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

United Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.63	$1.33B	$27.95	17.60
Regeneron Pharmaceuticals	$15.53B	5.65	$4.50B	$40.46	21.06

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

United Therapeutics has a net margin of 41.56% compared to Regeneron Pharmaceuticals' net margin of 27.86%. United Therapeutics' return on equity of 20.18% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

In the previous week, Regeneron Pharmaceuticals had 14 more articles in the media than United Therapeutics. MarketBeat recorded 45 mentions for Regeneron Pharmaceuticals and 31 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.43 beat Regeneron Pharmaceuticals' score of 0.85 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	23 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	22 Very Positive mention(s)	5 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

United Therapeutics currently has a consensus price target of $646.00, suggesting a potential upside of 31.30%. Regeneron Pharmaceuticals has a consensus price target of $800.36, suggesting a potential downside of 6.06%. Given United Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe United Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

United Therapeutics beats Regeneron Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to argenex?

argenex (NASDAQ:ARGX) and United Therapeutics (NASDAQ:UTHR) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

argenex currently has a consensus price target of $1,158.61, suggesting a potential upside of 9.78%. United Therapeutics has a consensus price target of $646.00, suggesting a potential upside of 31.30%. Given United Therapeutics' higher probable upside, analysts clearly believe United Therapeutics is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has a net margin of 41.56% compared to argenex's net margin of 32.19%. argenex's return on equity of 43.59% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
United Therapeutics	41.56%	20.18%	17.98%

In the previous week, United Therapeutics had 13 more articles in the media than argenex. MarketBeat recorded 31 mentions for United Therapeutics and 18 mentions for argenex. United Therapeutics' average media sentiment score of 1.43 beat argenex's score of 0.49 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	3 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
United Therapeutics	23 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

United Therapeutics has lower revenue, but higher earnings than argenex. United Therapeutics is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	15.54	$1.29B	$26.04	40.53
United Therapeutics	$3.18B	6.63	$1.33B	$27.95	17.60

60.3% of argenex shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

United Therapeutics beats argenex on 9 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and United Therapeutics (NASDAQ:UTHR) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Moderna presently has a consensus target price of $76.72, indicating a potential downside of 49.13%. United Therapeutics has a consensus target price of $646.00, indicating a potential upside of 31.30%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	30.97	-$2.82B	-$7.99	N/A
United Therapeutics	$3.18B	6.63	$1.33B	$27.95	17.60

Moderna has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

United Therapeutics has a net margin of 41.56% compared to Moderna's net margin of -141.43%. United Therapeutics' return on equity of 20.18% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
United Therapeutics	41.56%	20.18%	17.98%

In the previous week, Moderna had 56 more articles in the media than United Therapeutics. MarketBeat recorded 87 mentions for Moderna and 31 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.43 beat Moderna's score of 0.64 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	38 Very Positive mention(s)	15 Positive mention(s)	12 Neutral mention(s)	4 Negative mention(s)	8 Very Negative mention(s)	Positive
United Therapeutics	23 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.3% of Moderna shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

United Therapeutics beats Moderna on 12 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to Natera?

United Therapeutics (NASDAQ:UTHR) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

In the previous week, United Therapeutics had 3 more articles in the media than Natera. MarketBeat recorded 31 mentions for United Therapeutics and 28 mentions for Natera. United Therapeutics' average media sentiment score of 1.43 beat Natera's score of 1.15 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	23 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	24 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 41.56% compared to Natera's net margin of -7.11%. United Therapeutics' return on equity of 20.18% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Natera	-7.11%	-11.38%	-7.87%

United Therapeutics currently has a consensus price target of $646.00, indicating a potential upside of 31.30%. Natera has a consensus price target of $319.38, indicating a potential downside of 1.78%. Given United Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe United Therapeutics is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 5.1% of Natera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

United Therapeutics has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.63	$1.33B	$27.95	17.60
Natera	$2.71B	17.31	-$208.16M	-$1.36	N/A

United Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

Summary

United Therapeutics beats Natera on 12 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Revolution Medicines?

United Therapeutics (NASDAQ:UTHR) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

United Therapeutics currently has a consensus target price of $646.00, suggesting a potential upside of 31.30%. Revolution Medicines has a consensus target price of $200.74, suggesting a potential downside of 4.06%. Given United Therapeutics' higher probable upside, research analysts clearly believe United Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

United Therapeutics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.63	$1.33B	$27.95	17.60
Revolution Medicines	$11.58M	3,872.74	-$1.13B	-$8.82	N/A

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Revolution Medicines had 32 more articles in the media than United Therapeutics. MarketBeat recorded 63 mentions for Revolution Medicines and 31 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.43 beat Revolution Medicines' score of 0.78 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	23 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	27 Very Positive mention(s)	10 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	4 Very Negative mention(s)	Positive

United Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

United Therapeutics has a net margin of 41.56% compared to Revolution Medicines' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Revolution Medicines	N/A	-88.20%	-57.85%

Summary

United Therapeutics beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

Get United Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UTHR vs. The Competition

Export

Metric	United Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.99B	$3.99B	$7.21B	$12.67B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	17.60	12.25	272.68	25.23
Price / Sales	6.63	1,393.34	631.74	104.27
Price / Cash	15.54	105.29	76.98	52.08
Price / Book	3.30	16.59	12.99	6.10
Net Income	$1.33B	-$22.72M	$3.47B	$348.86M
7 Day Performance	-6.80%	-1.21%	-0.10%	-1.90%
1 Month Performance	-4.70%	11.27%	6.77%	1.96%
1 Year Performance	25.69%	53.12%	25.10%	15.30%

United Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UTHR United Therapeutics	4.7413 of 5 stars	$492.02 -4.0%	$646.00 +31.3%	+21.5%	$21.99B	$3.18B	17.60	1,400	Positive News Insider Trade High Trading Volume
REGN Regeneron Pharmaceuticals	4.0845 of 5 stars	$828.50 -0.7%	$801.70 -3.2%	+47.4%	$85.87B	$15.53B	20.48	15,410	Trending News
ARGX argenex	3.8505 of 5 stars	$1,011.11 -2.8%	$1,118.28 +10.6%	+49.4%	$65.05B	$4.25B	38.83	1,863	Analyst Forecast Gap Up
MRNA Moderna	1.5014 of 5 stars	$138.89 -4.3%	$74.31 -46.5%	+523.4%	$57.94B	$1.94B	N/A	4,700	Trending News Analyst Downgrade Options Volume Analyst Revision
NTRA Natera	2.4716 of 5 stars	$327.72 -1.3%	$319.38 -2.5%	+92.0%	$47.86B	$2.31B	N/A	6,140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UTHR) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Summary

How does United Therapeutics compare to argenex?

Summary

How does United Therapeutics compare to Moderna?

Summary

How does United Therapeutics compare to Natera?

Summary

How does United Therapeutics compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Which has more risk & volatility, UTHR or REGN?

Which has stronger earnings and valuation, UTHR or REGN?

Do institutionals and insiders hold more shares of UTHR or REGN?

Is UTHR or REGN more profitable?

Does the media prefer UTHR or REGN?

Do analysts rate UTHR or REGN?

Summary

How does United Therapeutics compare to argenex?

Do analysts recommend ARGX or UTHR?

Is ARGX or UTHR more profitable?

Does the media favor ARGX or UTHR?

Which has more volatility & risk, ARGX or UTHR?

Which has preferable earnings and valuation, ARGX or UTHR?

Do institutionals & insiders have more ownership in ARGX or UTHR?

Summary

How does United Therapeutics compare to Moderna?

Do analysts prefer MRNA or UTHR?

Which has stronger valuation & earnings, MRNA or UTHR?

Which has more volatility & risk, MRNA or UTHR?

Is MRNA or UTHR more profitable?

Does the media favor MRNA or UTHR?

Do institutionals and insiders have more ownership in MRNA or UTHR?

Summary

How does United Therapeutics compare to Natera?

Does the media prefer UTHR or NTRA?

Is UTHR or NTRA more profitable?

Do analysts rate UTHR or NTRA?

Do institutionals & insiders believe in UTHR or NTRA?

Which has preferable earnings and valuation, UTHR or NTRA?

Which has more volatility and risk, UTHR or NTRA?

Summary

How does United Therapeutics compare to Revolution Medicines?

Do analysts prefer UTHR or RVMD?

Which has better earnings & valuation, UTHR or RVMD?

Do institutionals & insiders hold more shares of UTHR or RVMD?

Does the media refer more to UTHR or RVMD?

Which has more risk & volatility, UTHR or RVMD?

Is UTHR or RVMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools